irinotecan, capecitabin, and avastin for advanced paget’s disease: a phase II trial.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400086142

Enrollment

Unknown

Registered

2024-06-26

Start date

2024-06-26

Completion date

Unknown

Last updated

2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

PAGET DISEASE

Interventions

treatment :irinotecan 180mg/m2 capecitabine 1000mg/m2 bid D1-14 bevacizumab 7.5mg/kg q3w

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Older than 18 years; 2. Target lesion according to RECIST 1.1 or skin lesion according to WHO criteria. 3. Enough relevant functions; PLT>70, HB>80 4. Consent form 5. ECOG 0-1. 6. Histology 7. ALT 3 months 11. Compliance 12. Contraception

Exclusion criteria

Exclusion criteria: 1. Major surgeries; 2. Uncontrolled hypertention; 3. HBV DNA > 2000 4. HIV positive 5. Unsuitable judged by investigators; 6. Hyperallergy 7. Other trials; 8. Allergy to antibodies; 9. Bleeding risk; 10. Mental disease;

Design outcomes

Primary

Measure	Time frame
Objective response rate, ORR ;	—

Secondary

Measure	Time frame
Progression-free survival, PFS;Disease control rate, DCR;Duration of remission, DOR;Overall survival,OS;	—

Countries

China

Contacts

Public Contactsheng zhang

Shanghai Cancer Center, Fudan University

wozhangsheng@hotmail.com+86 21 6782 2026

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026